Nausea and vomiting in pregnancy in relation to prolactin, estrogens, and XXXX : a prospective study.

@entity1 @entity390 @entity1420 @entity11111 @entity391 @entity53 @entity443
OBJECTIVE: To assess pregnancy hormone levels in relation to @entity390 with or without @entity391 . METHODS: In the context of a prospective cohort study, 262 white pregnant @entity1 in Boston were observed through delivery. Maternal blood was collected at 16 and 27 weeks' gestation and serum levels of @entity53 , @entity11111 , @entity1420 , prolactin, and @entity443 were determined. Information on sociodemographic and medical variables was collected through an interviewer-administered questionnaire and review of medical records. At the 27th gestational week, @entity390 with or without @entity391 at any time during the index pregnancy was ascertained. RESULTS: By the 27th gestational week, 209 @entity1 (79.8%) had experienced @entity390 with or without @entity391 . There was a substantial and statistically significant (P <.01) inverse association of prolactin with @entity390 with or without @entity391 at both the first and the second samplings, with or without adjustment for the other measured compounds. @entity53 was positively associated with @entity390 with or without @entity391 risk, but the association was evident only after adjustment for the other measured compounds (P values of.06 and.07 at the first and second samplings, respectively). We found no evidence that @entity11111 , @entity1420 , or @entity443 was related to @entity390 with or without @entity391 at either the 16th or the 27th week of pregnancy. CONCLUSION: Our results point to lower levels of prolactin and, perhaps, higher levels of @entity53 as contributing to or correlating with the occurrence of @entity390 with or without @entity391 at any time during the pregnancy until the 27th gestational week. We found no evidence that @entity11111 , @entity1420 , or @entity443 is associated with this condition.
